Get the Stockscreener App
2.29
4.98%
-0.12
After Hours:
2.30
0.010
+0.44%
Proqr Therapeutics N V stock is traded at $2.29, with a volume of 350.56K.
It is down -4.98% in the last 24 hours and up +4.57% over the past month.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
See More
Previous Close:
$2.41
Open:
$2.47
24h Volume:
350.56K
Relative Volume:
1.04
Market Cap:
$240.94M
Revenue:
$7.05M
Net Income/Loss:
$-30.43M
P/E Ratio:
-6.0454
EPS:
-0.3788
Net Cash Flow:
$21.84M
1W Performance:
-2.97%
1M Performance:
+4.57%
6M Performance:
+104.46%
1Y Performance:
+23.78%
1-Day Range:
$2.28
$2.47
1-Week Range:
$2.25
$2.58
52-Week Range:
$1.07
$4.62
Proqr Therapeutics N V Stock (PRQR) Company Profile
Compare PRQR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRQR
Proqr Therapeutics N V
|
2.29 | 253.88M | 7.05M | -30.43M | 21.84M | -0.3788 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-29-25 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-29-25 | Initiated | Evercore ISI | Outperform |
| Mar-10-25 | Upgrade | Citigroup | Neutral → Buy |
| Jan-10-25 | Initiated | Oppenheimer | Outperform |
| Oct-29-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Nov-08-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Mar-30-23 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Dec-22-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Feb-14-22 | Downgrade | Citigroup | Buy → Neutral |
| Feb-11-22 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| Feb-11-22 | Downgrade | Stifel | Buy → Hold |
| Feb-01-22 | Initiated | Raymond James | Strong Buy |
| May-03-21 | Initiated | Stifel | Buy |
| Mar-25-21 | Reiterated | Citigroup | Buy |
| Nov-03-20 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-12-19 | Reiterated | Chardan Capital Markets | Buy |
| Dec-19-18 | Initiated | RBC Capital Mkts | Outperform |
| Nov-15-18 | Initiated | Citigroup | Buy |
| Sep-19-18 | Initiated | Evercore ISI | Outperform |
| Sep-26-17 | Reiterated | JMP Securities | Mkt Outperform |
| Jun-20-16 | Initiated | Chardan Capital Markets | Neutral |
| Oct-15-14 | Initiated | Deutsche Bank | Buy |
| Oct-13-14 | Initiated | H.C. Wainwright | Buy |
View All
Proqr Therapeutics N V Stock (PRQR) Latest News
Risk adjusted return profile for ProQR Therapeutics N.V. analyzedJuly 2025 Update & Community Supported Trade Ideas - newser.com
Is ProQR Therapeutics N.V. stock a good choice for value investorsRate Cut & High Conviction Buy Zone Picks - newser.com
ProQR Therapeutics N.V. stock retracement – recovery analysisPortfolio Profit Report & AI Forecast for Swing Trade Picks - newser.com
Will ProQR Therapeutics N.V. stock outperform international peersRisk Management & Daily Growth Stock Tips - newser.com
ProQR Therapeutics to Participate in Upcoming Investor Conferences with Focus on RNA Editing Technology - Quiver Quantitative
ProQR to Participate in Upcoming Investor Conferences in October 2025 - GlobeNewswire
Oct 14–22, 2025: ProQR to Present at Three Investor Conferences; RNA Editing Panel Oct 21, webcasts available - Stock Titan
ProQR Therapeutics N.V. stock chart pattern explainedWeekly Profit Recap & AI Optimized Trade Strategies - newser.com
Quantitative breakdown of ProQR Therapeutics N.V. recent moveMarket Movement Recap & Fast Entry and Exit Trade Plans - newser.com
Risk vs reward if holding onto ProQR Therapeutics N.V.2025 Historical Comparison & AI Enhanced Trading Signals - newser.com
ProQR Therapeutics' (PRQR) Sell (D-) Rating Reiterated at Weiss Ratings - MarketBeat
ProQR Therapeutics N.V.'s (NASDAQ:PRQR) Price Is Out Of Tune With Revenues - simplywall.st
How ProQR Therapeutics N.V. (0PQ) stock reacts to new regulationsWeekly Trade Recap & Consistent Income Trade Recommendations - newser.com
Can you recover from losses in ProQR Therapeutics N.V.2025 Price Momentum & High Return Stock Watch Alerts - newser.com
What MACD and RSI say about ProQR Therapeutics N.V.Earnings Summary Report & Weekly High Potential Alerts - newser.com
Analyzing drawdowns of ProQR Therapeutics N.V. with statistical toolsDip Buying & Long-Term Growth Stock Strategies - newser.com
ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
How to escape a deep drawdown in ProQR Therapeutics N.V.Breakout Watch & Weekly Chart Analysis and Guides - newser.com
Will ProQR Therapeutics N.V. (0PQ) stock outperform energy sector in 2025Portfolio Risk Report & Fast Exit Strategy with Risk Control - newser.com
Should you wait for a breakout in ProQR Therapeutics N.V.Day Trade & Stepwise Swing Trade Plans - newser.com
Order flow analysis tools used on ProQR Therapeutics N.V.Price Action & Daily Stock Momentum Reports - newser.com
What MACD signals say about ProQR Therapeutics N.V.Market Volume Summary & Free Technical Pattern Based Buy Signals - newser.com
ProQR Therapeutics (NASDAQ:PRQR) Shares Cross Above 50-Day Moving AverageShould You Sell? - MarketBeat
What drives ProQR Therapeutics NV stock priceBearish Engulfing Patterns & Reduce Losses With Smart Exit Strategies - earlytimes.in
Tools to assess ProQR Therapeutics N.V.’s risk profile2025 Valuation Update & AI Based Buy and Sell Signals - newser.com
ProQR Therapeutics NV Stock Analysis and ForecastCurrency Fluctuation Impact & Low Risk Wealth Building - earlytimes.in
Proqr Therapeutics N V Stock (PRQR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):